Literature DB >> 15738278

Teaching old drugs new tricks: asthma therapy adjusted by patient perception or noninvasive markers.

P G Gibson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15738278     DOI: 10.1183/09031936.05.00002805

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  7 in total

Review 1.  Asthma exacerbations . 4: Prevention.

Authors:  J M FitzGerald; P G Gibson
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

2.  Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.

Authors:  Gunnar Johansson; Emma B Andreasson; Per E Larsson; Claus F Vogelmeier
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study.

Authors:  René Aalbers; Martin Boorsma; Hanneke J van der Woude; René E Jonkers
Journal:  Respir Res       Date:  2010-05-28

4.  Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study.

Authors:  René E Jonkers; Theo A Bantje; René Aalbers
Journal:  Respir Res       Date:  2006-12-04

5.  Asthma exacerbations: prevention is better than cure.

Authors:  Dominick E Shaw; Ruth H Green; Peter Bradding
Journal:  Ther Clin Risk Manag       Date:  2005-12       Impact factor: 2.423

6.  Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations.

Authors:  P Kuna; M J Peters; A I Manjra; C Jorup; I P Naya; N E Martínez-Jimenez; R Buhl
Journal:  Int J Clin Pract       Date:  2007-03-16       Impact factor: 2.503

7.  A smarter way to manage asthma with a combination of a long-acting beta(2)-agonist and inhaled corticosteroid.

Authors:  Olof Selroos
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.